Advertisement

Topics

Research-Fazits zu Sky, Shell, Astrazeneca ...

02:52 EDT 16 Oct 2017 | FinanzNachrichten

ALPHAVALUE HEBT SKY AUF 'ADD' (REDUCE) BARCLAYS HEBT ZIEL FÜR SHELL AUF 2850 (2750) PENCE - 'OVERWEIGHT' CREDIT SUISSE HEBT ASTRAZENECA AUF 'OUTPERFORM' (NEUTRAL) - ZIEL 5800 (4800) PCREDIT SUISSE ...

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Research-Fazits zu Sky, Shell, Astrazeneca ...

NEXT ARTICLE

More From BioPortfolio on "Research-Fazits zu Sky, Shell, Astrazeneca ..."

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topics

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.